Skip to main content
Premium Trial:

Request an Annual Quote

Cedars-Sinai Joins GenomeDx-Led Prostate Cancer Genomic Data Sharing Platform

NEW YORK (GenomeWeb) – GenomeDx Biosciences today announced a partnership with Cedars-Sinai Medical Center on the Decipher Genomics Resource Information Database (GRID).

Decipher GRID is a clinical genomics data sharing program aimed to provide clinicians with information on prostate cancer and other urologic cancers. Under the terms of the agreement, Cedars-Sinai will treat prostate cancer patients using the platform as well as use the firm's Decipher Prostate Cancer Classifier test to aid treatment decisions. GenomeDx will conduct whole-genome profiling for patients included in the program and match those data to prospectively collected clinical outcomes for patients treated at major cancer centers.

Financial and other details of the agreement were not disclosed.

GRID is the largest accessible genomic expression database for urologic cancers, GenomeDx said in a statement. "Through partnerships with groups like Cedars-Sinai we can marry the power of genomic information with prospective clinical outcomes for patients," GenomeDx CEO Doug Dolginow said.

San Diego- and Vancouver, Canada-based GenomeDx launched Decipher GRID in May, initially partnering with Thomas Jefferson University's Sidney Kimmel Cancer Center.

In 2014, Cedars-Sinai tapped N-of-One to provide database services.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more